{"id":"NCT04181723","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDERâ„¢)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-06","primaryCompletion":"2021-10-28","completion":"2021-10-28","firstPosted":"2019-11-29","resultsPosted":"2024-04-08","lastUpdate":"2024-04-08"},"enrollment":187,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rett Syndrome"],"interventions":[{"type":"DRUG","name":"Trofinetide","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Drug - Trofinetide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To investigate the efficacy of treatment with oral trofinetide versus placebo in females with Rett syndrome","primaryOutcome":{"measure":"Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Drug - Trofinetide","deltaMin":-4.9,"sd":0.94},{"arm":"Placebo","deltaMin":-1.7,"sd":0.9}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0175"}]},"eligibility":{"minAge":"5 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":["38363467","37460385","37291210","35149233"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":93},"commonTop":["Diarrhoea","Vomiting","Pyrexia","Seizure","Decreased appetite"]}}